Comparative Pharmacology
Head-to-head clinical analysis: CECLOR CD versus SPECTRACEF.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CECLOR CD versus SPECTRACEF.
CECLOR CD vs SPECTRACEF
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefaclor, a second-generation cephalosporin, inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby disrupting peptidoglycan cross-linking.
Cefditoren, a third-generation cephalosporin, inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.
250-500 mg orally every 8 hours; extended-release form (CECLOR CD) 375-750 mg orally every 12 hours.
400 mg orally twice daily for 10-14 days.
None Documented
None Documented
Terminal elimination half-life: ~0.6-0.9 hours (prolonged in renal impairment)
Terminal elimination half-life: 2.5 hours (range 2.0-3.0 hours) in healthy adults; prolonged in renal impairment (up to 10 hours in severe impairment)
Renal: ~80% unchanged; biliary/fecal: ~20%
Renal: 88% as unchanged drug, Fecal: negligible, Biliary: minimal
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic